ReviewCancer biology & medicine2020
Cancer burden in China: trends, risk factors and prevention.
Review in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Upper gastrointestinal endoscopic screening uptake and associated factors in East Asia: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Trends and hotspots in research related to tumor immune escape: bibliometric analysis and future perspectives.Frontiers in immunology · 2025Pooled it
- High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer.Cancer biology & medicine · 2023Pooled it
- Effectiveness of smoking cessation on the high-risk population of lung cancer with early screening: a systematic review and meta-analysis of randomized controlled trials until January 2022.Archives of public health = Archives belges de sante publique · 2023Pooled it
- Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.BMC cancer · 2021Pooled it
- Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.Journal of cancer research and clinical oncology · 2023Trial
- Burden of cancer in China from 1990 to 2023 and projections to 2050.Science China. Life sciences · 2026Article
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Expression of p16 and p53 proteins in cervical cancer cases in a tertiary centre in Ghana: an immunohistochemical study.BMC cancer · 2026Article
- Bayesian model prediction of colorectal cancer incidence in Jiangsu Province, China, a cancer registry-based study.BMC public health · 2026Article
- Real-World Evidence on Hospitalization Costs of Pediatric Neoplasm Patients in China: Patterns, Trends, and Associated Factors From a Retrospective Cohort Study.Cancer medicine · 2026Article
- Combined Impact of Smoking Duration and Malnutrition on Cancer Survival: Insights Into Systemic Inflammation.Journal of cachexia, sarcopenia and muscle · 2026Article
- Global, regional, and national burden of lip and oral cavity cancer and its attributable risk factors from 1990 to 2021: an analysis of the Global Burden of Disease study 2021.International journal of clinical pharmacy · 2026Article
- Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy.International journal of surgery (London, England) · 2026Article
- Comprehensive pan-cancer analysis of RPRD1B as a promising diagnostic and prognostic biomarker.Discover oncology · 2026Article
- Trends in colorectal cancer mortality in China from 2004 to 2021: an epidemiological analysis based on national disease surveillance data.Frontiers in oncology · 2026Article
- Equity in the allocation of oncology bed resources in China: Longitudinal data from 2008 to 2022.PloS one · 2026Article
- A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications.Journal of Cancer · 2026Review
- Cancer burden and the contributions of risk factors in China: A systematic analysis for the Global Burden of Disease Study 2021.Chinese medical journal · 2025Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the most populous country in the world, China has made strides in health promotion in the past few decades. With the aging population, the burden of cancer in China continues to grow. Changes in risk factors for cancer, especially diet, obesity, diabetes, and air pollution, continue to fuel the shift of cancer transition in China. The burden of upper gastrointestinal cancer in China is decreasing, but still heavy. The rising burden of colorectal, prostate, and breast cancers is also significant. Lung cancer became the top cause of cancer-related deaths, together with smoking as the most important contributor to cancer deaths. The Chinese government has taken several approaches to control cancer and cancer-related risk factors. Many achievements have been made, but some challenges remain. Health China 2030 is ambitious and depicts a bright vision of the future for cancer control in China. The decrease in the cancer burden in China will require cross-sector collaboration and coordinated efforts on primary and secondary preventions by governments, public health organizations, and individuals. In this review, we describe the trends of cancer burden and discuss cancer-related risk factors in China, identifying strategies to reduce the burden of cancer in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.